Three-dimensional quantitative structure activity relationship (QSAR) of cytotoxic active 3,5-diaryl-4,5-dihydropyrazole analogs: a comparative molecular field analysis (CoMFA) revisited study

Chemistry Central Journal

Abdel-Sattar S Hamad Elgazwy³  DaliaH S Soliman²  Saad R Atta-Allah³  Diaa A Ibrahim¹ 

[1] National Organization for Drug Control & Research, P.O. Box: 29, Cairo, Egypt

[2] Department of pharmaceutical chemistry, Faculty of Pharmacy (girls' branch), Al-Azhar University, Nasser city, Cairo, Egypt

[3] Department of Chemistry Faculty of Science, Ain Shams University, Abbassia, 11566, Cairo, Egypt

关键词: CoMFA;    QSAR;    Antitumor;    1-(3,5-diaryl-4,5-dihydropyrazol-1-yl)ethanethione;    3,5-diaryl-4,5-dihydropyrazole-1-carbothioamide;   

Others  :  788139
DOI  :  10.1186/1752-153X-6-50

 received in 2012-01-19, accepted in 2012-04-26,  发布年份 2012

【 摘 要 】

In vitro antitumor evaluation of the synthesized 46 compounds of 3,5-diaryl-4,5-dihydropyrazoles against EAC cell lines and 3D QSAR study using pharmacophore and Comparative Molecular Field Analysis (CoMFA) methods were described. CoMFA derived QSAR model shows a good conventional squared correlation coefficient r² and cross validated correlation coefficient r²cv 0.896 and 0.568 respectively. In this analysis steric and electrostatic field contribute to the QSAR equation by 70% and 30% respectively, suggesting that variation in biological activity of the compounds is dominated by differences in steric (van der Waals) interactions. To visualize the CoMFA steric and electrostatic field from partial least squares (PLS) analysis, contour maps are plotted as percentage contribution to the QSAR equation and are associated with the differences in biological activity.

Background

Pyrazole derivatives exhibit a wide range of biological properties including promising antitumor activity. Furthermore, Aldol condensation assisted organic synthesis has delivered rapid routes to N-containing heterocycles, including pyrazoles. Combining these features, the use of chalconisation-assisted processes will provide rapid access to a targeted dihydropyrazoles library bearing a hydrazino 3D QSAR study using pharmacophore and Comparative Molecular Field Analysis (CoMFA) methods were described for evaluation of antioxidant properties.

Results

Chalcones promoted 1 of the 2 steps in a rapid, convergent synthesis of a small library of hydrazinyl pyrazole derivatives, all of which exhibited significant antitumor activity against Ehrlich Ascites Carcinoma (EAC) human tumor cell line comparable to that of the natural anticancer doxorubicin, as a reference standard during this study. In order to understand the observed pharmacological properties, quantitative structure-activity relationship (3D QSAR) study was initiated.

Conclusions

Chalcones heating provides a rapid and expedient route to a series of pyrazoles to investigate their chracterization scavenging properties. Given their favorable properties, in comparison with known anticancer, these pyrazole derivatives are promising leads for further development and optimization.

【 授权许可】

   
2012 Hamad Elgazwy et al.; licensee Chemistry Central Ltd.

【 图 表 】

Scheme 1

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Seymour L: Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 1999, 25:301-312.
• [2]Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61(2):203-212.
• [3]Hubbard SR, Till JH: Protein tyrosine kinase structure and function. Annu Rev Biochem 2000, 69:373-398.
• [4]Dai Y, Guo Y, Frey RR, Ji Z, Curtin ML, Ahmed AA, Albert DH, Arnold L, Arries SS, Barlozzari T, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Pease LJ, Stewart KD, Stoll VS, Tapang P, Wishart N, Davidsen SK, Michaelides MR: Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2005, 48(19):6066-6083.
• [5]Manfredini S, Bazzanini R, Baraldi PG, Guarneri M, Simoni D, Marongiu ME, Pani A, Tramontano E, La Colla P: Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides. J Med Chem 1992, 35(5):917-924.
• [6]Manfredini S, Bazzanini R, Baraldi PG, Bonora M, Marangoni M, Simoni D, Pani A, Scintu F, Pinna E, Pisano L, La Colla P: Pyrazole-related nucleosides. 4. Synthesis and antitumor activity of some 1-tetrahydropyranyl-4-substituted pyrazoles. Anticancer Drug Des 1996, 11(3):193-204.
• [7]Park HJ, Lee K, Park SJ, Ahn B, Lee JC, Cho H, Lee KI: Identification of antitumor activity of pyrazole oxime ethers. Bioorg Med Chem Lett 2005, 15(13):3307-3312.
• [8]Comber RN, Gray RJ, Secrist JA III: Acyclic analogues of pyrazofurin: syntheses and antiviral evaluation. Carbohydr Res 1991, 216:441-452.
• [9]Elgazwy AS, Ismail NS, Elzahabi HS: A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors. Bioorg Med Chem 2010, 18(21):7639-7650.
• [10]Temple C Jr, Elliot RD, Montgomery JA: Pyrido[2,3-d]pyrimidines. The synthesis of the 5-deaza analogs of aminopterin, methotrexate, folic acid, and N10-methylfolic acid. J Org Chem 1982, 47:761-764.
• [11]Taylor EC, Palmer DC, George TJ, Fletcher SR, Tseng CP, Harrington PJ, Beardsley GP, Dumas DJ, Rosowsky A, Wick M: Synthesis and biological activity of L-5-deazafolic acid and L-deazaaminopterin: synthetic strategies to 5-deazapteridines. J Org Chem 1983, 48:4852-4860.
• [12]Stone SR, Montgomery JA, Morrison JF: Inhibition of dihydrofolate reductase from bacterial and vertebrate sources by folate, aminopterin, methotrexate and their 5-deaza analogues. Biochem Pharmacol 1984, 33(2):175-179.
• [13]Grivsky EM, Lee S, Sigel CW, Duch DS, Nichol CA: Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido [2,3-d]pyrimidine. J Med Chem 1980, 23(3):327-329.
• [14]Ensminger WD, Grindey GB, Hoglind JA: Advances. In Cancer Chemotherapy. Vol. 1st edition. Edited by Rosowsky A. New York: Marcel Dekker; 1979:61-109.
• [15]DeGraw JI, Christie PH, Kisliuk RL, Gaumont Y, Sirotnak FM: Synthesis and antifolate properties of 10-alkyl-5,10-dideaza analogues of methotrexate and tetrahydrofolic acid. J Med Chem 1990, 33(2):673-677.
• [16]Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG: Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. J Med Chem 1985, 28(7):914-921.
• [17]Havrylyuk D, Kovach N, Zimenkovsky B, Vasylenko O, Lesyk R: Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch Pharm (Weinheim) 2011, 344(8):514-22.
• [18]Elgemeie GH, Mohamed MA, Jones PG: N-(3-Cyano-2-oxo-2,5,6,7,8,9-hexahydro-1 H-cyclohepta[b]pyridin-1-yl)-4-methylbenzenesulfonamide. Acta Crystallogr E 2002, 58:1293-1295.
• [19]Toda F, Tanaka K, Hami K: Aldol condensation in the absence of solvent:acceleration of the reaction and enhancement of the stereochemistry. J Chem Soc Perkin Trans 1990, 1:3207-3209.
• [20]Palleros DR: Solvent-free synthesis. J Chem Ed 2004, 81:1345-1347.
• [21]Comisar CM, Savage PE: Kinetics of crossed aldol condensations in high-temperature water. Green Chem 2004, 6:227-231.
• [22]Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M: CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 1983, 4(2):187-217.
• [23]Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I, Pavlik PA: A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Des 1993, 7(1):83-102.
• [24]Cramer RD, Bunce JD, Patterson DE: Frank … QSAR studies. Quant. Struct. Act. Relat. 1988, 7:18-25.
• [25]Kubinyi H (Ed): 3D QSAR in Drug Design. Theory, Methods and Applications. Leiden: ESCOM; 1993.
• [26]Kubinyi H, Folkers G, Martin YC (Eds): 3D QSAR in Drug Design. Vols. 2. 3rd edition. Dordrecht: Kluwer; 1998.
• [27]Blankley CJ, et al.: Structure Property Correlations in Drug Research. Austin: Academic; 1996:111-177.
• [28]Martin YC, Kim K-H, Lin CT: Advances in Quantitative Structure Property Relationships. Vol. I edition. Edited by Charton M. Greenwich: JAI Press; 1996:1-52.
• [29]Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83(11):757-766.
• [30]Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989, 81(14):1088-1092.
• [31]Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112.
• [32]Al-Abd AM, Lee JH, Kim SY, Kun N, Kuh HJ: Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci 2008, 99(2):423-431.